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KNEE OSTEOARTHRITIS COMBINATION THERAPY WITH
HYALURONIC ACID, CHONDROITINE SULFATE AND GLUCOSAMINE
AFTER ARTHROSCOPIC LAVAGE: LONG-TERM RESULTS
L.V. Luchikhina, O.I. Mendel, D.A. Antonov. RSMU, Moscow, Russian
Federation
Purpose: Purpose to study the efﬁciency therapy of arthroscopic lavage
in combination with subsequent intra articular injection of hyaluronic
acid and combined drug of chondroitin sulfate and glucosamine
hydrochloride at short- and long-term outcomes.
Methods: One-hundred-forty-two patients with knee osteoarthritis
(OA) were examined with accordance with the American College of
Rheumatology criteria and randomized into 3 groups:
1. Group 1 consisted of 40 patients only after arthroscopic lavage;
2. Group 2 comprised 42 patients who were administered hyaluronic
acid (RusVisc ) after arthroscopic lavage;
3. Group 3 comprised 40 patients who were administered combined
drug of chondroitin sulfate and glucosamine hydrochloride (ARTRA)
and hyaluronic acid after arthroscopic lavage.
Clinical evaluation encompassed pain while walking, resting, and
moving (by a visual analogue scale), limited ability in covering 100 m
(by a 5-point scale), general clinical evaluation (by a 5-point ordinal
scale), the presence or absence of pain after 100-m walking, as well as
resting pain (its presence or absence).
Results: The treatment effect evaluated using different indicators was
comparably positive in all 3 groupswithin 3months. Following3months
of therapy, its effect remained stable and even better in Group 2 and
Group 3. Groups 2 and 3 showed a particularly noticeable superiority a
year later. There were excellent and good results in 88 and 91% respec-
tively, and 47.5% inGroup1.Moreover, excellent resultswere observed in
51% of patients in Group 3, and in 45% in Group 2. The clinical symptoms
of the disease were absent in 66% of patients in Group 3, in 58% in Group
2 and in only 15% in Group 1. Moreover, Group 1 showed worsening and
20% of the patients had no effect. This trend was also seen while evalu-
ating the therapeutic effectiveness in different periods. Thus, after
therapy, no substantial difference was found in all groups, but 3 months
later this difference was as many as 0.8 scores and a year later Group 2
and Group 3 had many points in its favor (1.2 and 1.6 scores).
Conclusions: Arthroscopic lavage followed by the administration of
hyaluronic acid makes it possible to prevent the negative effect of a
washing liquid on the metabolism and structure of the articular carti-
lage. Complex therapy with hyaluronic acid and co-formulated drug of
chondroitin sulfate and glucosamine hydrochloride allows to achieve a
long-term effect against the major clinical symptoms (joint pain and
function) affecting the quality of life. The effect depended on the
magnitude of cartilage changes according to arthroscopic data and
failed to be related to age and disease duration. The magnitude of car-
tilage changes may be a predictor of response to treatment.
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INTRA-ARTICULAR ADMINISTRATIONS OF JONEXA IN PATIENTS
WITH SYMPTOMATIC OSTEOARTHRITIS OF THE HIP. DATA FROM A
MONOCENTRIC COHORT STUDY
A. Migliore, E. Bizzi, U. Massafra, F. Vacca, F. Giovannangeli,
S. Tormenta. S.Pietro FBF Hosp., Rome, Italy, Rome, Italy
Purpose: Severalmedical devices are at nowdisposable for intra-articular
use in patients affected by hip Osteoarthritis (OA) and several data have
been produced in order to support their use. At now there are no reports
on cohorts of patients undergoing intra-articular hip injections with
Jonexa showing its safety and efﬁcacy proﬁles in real life after commer-
cialization. Jonexa (Hylastan SGL-80) is a sterile, colorless, non-pyrogenicTable 1
Efﬁcacy outcome measures at each visit: VAS pain mean scores, Lequesne index
mean scores, NSAID consumption mean scores
Parameters Baseline 3 months 6 months
OA Pain VAS 7.01 3.89* 4.10*
Lequesne index 10.11 6.32* 6.11*
NSAID consumption 6,98 4.0* 4.0*
* p < 0,001 when compared with baseline values.elastoviscous ﬂuid, with a neutral pH and osmolality compatible with
synovial ﬂuid. Hylastan SGL-80 is manufactured from hylastan, a divinyl
sulfone chemically crosslinked sodium hyaluronate (HA) gel and sodium
hyaluronate ﬂuid characterized by a 80:20 gel to ﬂuid ratio. The sodium
hyaluronate used in the preparation of hylastan SGL-80 is derived from
bacterial fermentation. Jonexa is commercialized in Italy since September
2010 for intra_articular use in patients affected by osteoarthritis (OA).
Jonexa is expected to produce a symptom relief of at least 26weeks when
injected intra-articularly in patients affected by symptomatic OA.
This study was performed to report data on safety and efﬁcacy proﬁles
of Jonexa in intra-articular injections of the hip in a cohort of patients
affected by hip OA from a 6 months followup monocentric study.
Methods: Adult patients suffering from hip OA grade 1 to 3 according to
Kellgren and Lawrence grading were considered eligible for the study.
Patients were injected with one syringe (4 ml) of Jonexa at baseline by
ultrasound guidance following Migliore-Tormenta technique and were
then observed by a control visit performed 3months and 6months after
injection. The efﬁcacy was assessed by using the Lequesne index and
VAS pain score at baseline and, then, at every control visit. NSAIDs
consumption was also evaluated as the number of days in the month
previous to baseline visit or control visit where patient needed to
assume a pain killer for knee OA. Safety was assessed by recording any
adverse event during the follow up period, considering both transient
pain effects and any other eventual side effects.
Results: 41 patients, 21 males and 20 females, were enrolled in the
study; 11 had bilateral hip OA. All patients received one intra-articular
injection of Jonexa for every hip affected by OA; a total of 52 injections
was performed in this study. All patients reached the 6 months fol-
lowup visit. Mean scores obtained at each visit after baseline show an
improvement when compared with baseline with a statistically sig-
niﬁcant difference, p < 0,001 for every time point (Tab.1). No infectious
complications were reported. 4 patients (9,75% of total patients), for a
total of 5 injections (9,61% of total injections), reported a transient
discomfort in the treated hip for 1-3 days after injection that regressed
spontaneously or with paracetamol 1g twice or three times a day.
Conclusions: Our data suggest that beneﬁcial effects obtained by the
intra-articular injection of the hip joint may be evident at three
months after ﬁrst injection and seem to be maintained over six months.
Further results will be obtained by the completion of this observational
study.878
VISCOSUPPLEMENTATION IS NOT AN ALTERNATIVE TO HIP JOINT
SURGERY IN PATIENTS WITH SEVERE HIP OSTEOARTHRITIS.
RESULTS OF A “REAL LIFE” CLINICAL SURVEY IN 137 PATIENTS
T. Conrozier, A. Walliser-Lohse, J-C. Balblanc, M. Bossert. Belfort
Montbeliard Hosp., Belfort, France
Purpose: To compare patient’s satisfaction and treatment efﬁcacy of a
single hyaluronic acid (HA) intra-articular injection in patients with
moderate hip osteoarthritis (OA) and in patients waiting for total hip
replacement.
Methods:Multicenter standardized follow-up.137 consecutive patients
treated with a single intra-articular injection of HANOX M-XL (cross-
linked HA 1.5% þmannitol) for symptomatic hip OA were included in
the study. Demographic data, imaging guidance (ﬂuoroscopy or ultra-
sonography), pain on a 10 point Likert scale, patient’s self-evaluation of
efﬁcacy, satisfaction with the treatment and tolerability were obtained.
Patients were classiﬁed into two groups: Those for which the visco-
supplementation was the last resort before total hip arthroplasty (THA
group, N ¼ 41) and those who would not consider surgery in the short
term (Non Surgery- NS group; N ¼ 96).
Results: The percentage of patients very satisﬁed/satisﬁed and not
really satisﬁed/not satisﬁed with the treatment was 54.7% and 45.3%
respectively. In satisﬁed patients the decrease of analgesics/NSAIDs
consumption was>75% in 60.5% of cases. Efﬁcacy was unrelated to
gender, age, and guidance. It was highly correlated with both sat-
isfaction and pain (p < 0.0001). 65.9% of the NS group patients were
satisﬁed with the treatment versus 15.5% of those belonging to the THA
group (p < 0.0001). Tolerability was very good/good in 115 patients
(85.2%) and unrelated to disease severit, imaging guidance and efﬁcacy.
Conclusions: These data suggest that despite viscosupplementation
with HANOX-M-XL is safe and efﬁcient in moderate hip OA it is not an
alternative to surgery in advanced disease.
